UNSPSC 51144015: Methylphenidate hydrochloride

This classification denotes a central nervous system stimulantt and dopamine uptake inhibitor with the molecular formula C14H19NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B3SC438HI, chemically known as 2-piperidineacetic acid, .alpha.-phenyl-, methyl ester, hydrochloride but more generally known as methylphenidate hydrochloride, which bears US NIH Compound Identifier 4158.

UNSPSC 51144015 Methylphenidate hydrochloride is a Commodity code that in recent state and local procurement reflects a much broader pharmaceutical and health products acquisition strategy than the code's specific drug name suggests. State and local governments are using this code to solicit pharmaceuticals, over-the-counter products, and drug-related health supplies through competitive and cooperative purchasing mechanisms. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida procured naloxone and drug deactivation systems through an IFB; the Texas Health and Human Services Commission issued an RFI exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and OTC products through an RFP. These solicitations reflect state and local demand for pharmaceutical supply chain management, cost control through competitive bidding or direct manufacturer relationships, and standardized sourcing across multiple jurisdictions and facilities.

Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP's cooperative framework extending into Oregon and other participating jurisdictions. The Seminole County IFB60459723LAS, posted June 30, 2026 with a due date of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas HHS RFI HHS0017013, posted April 3, 2026, gathered vendor capability information on direct-to-manufacturer prescription programs to support state pharmacy benefit objectives. The MMCAP RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, established multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with pricing weighted at 75 percent, a 3 percent administrative fee, and performance penalties of $200 to $1,500 per violation. Vendors typically must meet cGMP and Drug Supply Chain Security Act compliance, maintain specified insurance coverage, and demonstrate EDI capability and pricing flexibility across multiple net-price formats.